a. Deadline: 16th September 2025

b. Standardize methods to detect MNPs in the environment and human body.

c. Study how MNPs affect human health at the molecular and cellular level.

d. Use realistic samples to assess toxicity based on size, shape, and composition.

e. Develop in-vitro, in-vivo, and in-silico models for exposure and risk assessment.

f. Conduct biomonitoring and long-term studies on health impacts.

g. Evaluate workplace exposure and propose mitigation strategies.

h. Examine interactions between MNPs and other pollutants.

i. Investigate how MNPs are processed and eliminated in the body.

j. Share data with EU platforms and engage policymakers for regulatory impact.

a. Deadline: 16th September 2025

b. Conduct clinical studies to test safety, efficacy, and mechanisms of new therapeutic interventions.

c. Integrate complementary non-pharmaceutical approaches (e.g. digital tools, neurostimulation, psychotherapy).

d. Use technologies like AI and wearables to monitor treatment outcomes and support home-based care.

e. Analyse biomarkers, imaging, and omics data to personalize interventions and develop surrogate endpoints.

f. Leverage and generate data using biobanks, registries, and real-world cohorts in line with FAIR principles.

g. Design interventions with input from patients, caregivers, and clinicians; apply gender-sensitive approaches.

h. Collaborate with EU research infrastructures and health authorities to support translation and adoption.

a. Deadline: 16th September 2025

b. Develop trustworthy, ethical Generative AI tools to support clinical decision-making using diverse multimodal health data.

c. Demonstrate added value in at least two medical use cases with proven clinical utility and superior outcomes vs. standard of care.

d. Involve healthcare professionals and patients in design, testing, and training to ensure usability and inclusivity.

e. Create frameworks for bias mitigation, model transparency, and explainability.

f.  Address ethical, legal, and societal implications (ELSI), including liability and data privacy.

g. Align with EU standards, FAIR principles, and GDPR compliance.

h. Use EU-developed models and infrastructure; open-source approaches encouraged.

i. Connect with European Health Data Space, EOSC, AI Factories, and other EU initiatives.

j. Include regulatory strategy and sustainability planning from early stages.

a. Deadline: 16th September 2025

b. Support Phase I, II, or I/II clinical trials for novel biotech-derived therapies (e.g. monoclonal antibodies, ATMPs, RNA therapies, nano-based drugs).

c. Target the transition from preclinical to early clinical development, not full market authorization.

d. Proposals must show strong economic potential and commercialization strategy for the EU market.

e. Require an exploitation plan including IP strategy, financing roadmap, and EU deployment path.

f. Focus on therapies for patient populations with high unmet needs or large clinical impact.

g. Projects must involve multidisciplinary consortia (SMEs, academia, clinicians, research orgs).

h. Maximum project duration: 4 years.

i. Clinical study details must be included in the dedicated annex template

a. Deadline: 29th October 2025

b. Any field of science or tech – up to €3M/project.

c. Focus on proof of principle for radically new science-to-technology concepts.

d. Biotech for climate-resilient crops

e. Generative AI for cancer diagnosis & treatment

f. Autonomous robot collectives for construction

g. Circular “waste-to-value” devices

h. EU Member States (at least 3 different entities)

a. Deadline: October 2025

b. Early-career researchers (2–7 years post-PhD) with outstanding track records to become independent research leaders.

c. Researchers of any nationality

d. Open to any research field (“bottom-up” approach)

e. Research must take place in an EU Member State or associated country

f. Up to €1.5M for 5 years (pro rata for shorter projects).

g. Additional €1M for start-up costs, major equipment, or relocation from a non-EU country.

h. Covers 100% of direct costs + 25% indirect cost contribution

a. Deadline 28th August 2025

b. Up to €2.5 million for 5 years.

c. Additional up to €1 million for relocation to EU, major equipment, fieldwork or large-scale experiments

d. Fund established research leaders with a proven track record to pursue ground-breaking, high-impact research

e. Researchers of any nationality can apply if conducting research in an EU Member State or Associated Country

f.  Host Institutions must be legal entities based in the EU/AC, including public/private bodies, universities, or international organisations (e.g. CERN, EMBL)

g. Proposals must demonstrate ambition, novelty, and feasibility

a. Deadline: 18th September 2025

b. Support ERC-funded Principal Investigators in exploring the commercial or societal innovation potential of their ERC research.

c. Applies to all ERC main grants (Starting, Consolidator, Advanced, Synergy)

d. €150,000 lump sum for a project duration of up to 18 months

e. Covers all direct and indirect costs (personnel, subcontracting, materials, etc.)

f. Intended for early-stage valorisation, tech transfer, or market readiness

a. Deadline: November 2025

b. Up to €10 million for up to 6 years

c. Additional €4 million available for start-up costs, relocating PIs, major equipment, and access to large facilities.

d. Support 2–4 Principal Investigators (PIs) to jointly tackle ambitious scientific challenges unachievable by individuals alone.

e. Encourage breakthroughs through cross-disciplinary collaboration, novel methodologies, or unconventional approaches

f. One PI (non-corresponding) may be based outside the EU/Associated Countries